Search Results - "Jiménez Velasco, A."

P700: TREATMENT‐FREE REMISSION (TFR) AFTER DASATINIB IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML‐CP) AND DEEP MOLECULAR RESPONSE (DMR): FINAL 5‐YEAR RESULTS OF DASFREE by Shah, N. P., García‐Gutiérrez, V., Jiménez‐Velasco, A., Saussele, S., Rea, D., Mahon, F.‐X., Levy, M. Y., Gómez‐Casares, M. T., Mauro, M. J., Sy, O., Martin‐Regueira, P., Lipton, J. H.

Get full text

ASPP1, a common activator of TP53, is inactivated by aberrant methylation of its promoter in acute lymphoblastic leukemia by AGIRRE, X, ROMAN-GOMEZ, J, TORRES, A, MINNA, J. D, PROSPER, F, JIMENEZ-VELASCO, A, GARATE, L, MONTIEL-DUARTE, C, NAVARRO, G, VAZQUEZ, I, ZALACAIN, M, CALASANZ, M. J, HEINIGER, A

“…We have analyzed the regulation and expression of ASPP members, genes implicated in the regulation of the apoptotic function of the TP53 tumor-suppressor gene,…”
Get full text

Current opinion and consensus statement regarding the diagnosis, prognosis, and treatment of patients with essential thrombocythemia: a survey of the Spanish Group of Ph-negative Myeloproliferative Neoplasms (GEMFIN) using the Delphi method by Besses, C., Hernández-Boluda, J. C., Pérez Encinas, M., Raya, J. M., Hernández-Rivas, J. M., Jiménez Velasco, A., Martínez Lopez, J., Vicente, V., Burgaleta, C.

“…The current consensus on the diagnosis, prognosis, and treatment of essential thrombocythemia (ET) is based on experts’ recommendations. However, several…”
Get full text

Real-time PCR quantification of haematopoietic chimerism after transplantation: a comparison between TaqMan and hybridization probes technologies by MARTINEZ-LOPEZ, J., CROOKE, A., GRANDE, S., AYALA, R., JIMÉNEZ-VELASCO, A., GAMARRA, S., MENEU, J. C., GILSANZ, F.

“…Summary This study aimed to compare the sensitivity and accuracy of two methods of quantitative real‐time polymerase chain reaction (qrt‐PCR), in order to…”
Get full text

993: Quantification of donor/recipient chimerism in leukemia by digital PCR by Hayashibara, K, Jiménez-Velasco, A

Get full text

Clinical outcome after sex-mismatched allogeneic stem cell transplantation from human lymphocyte antigen-identical sibling donors: influence of stem cell source by Gallardo, D, Pérez-García, A, de la Cámara, R, Iriondo, A, Jiménez-Velasco, A, Torres, A, Brunet, S, Urbano-Ispizúa, A, Vallejo, C, Encuentra, M, Caballero, D, Espigado, I, Serrano, D, Barrenetxea, C, Ribera, J M, de la Rubia, J

Get full text

UGT2B17 minor histocompatibility mismatch and clinical outcome after HLA-identical sibling donor stem cell transplantation by Santos, N, Rodríguez-Romanos, R, Nieto, J B, Buño, I, Vallejo, C, Jiménez-Velasco, A, Brunet, S, Buces, E, López-Jiménez, J, González, M, Ferrá, C, Sampol, A, de la Cámara, R, Martínez, C, Gallardo, D

“…Minor histocompatibility Ags (mHags) have been implicated in the pathogenesis of GVHD after allogeneic hematopoietic stem cell transplantation (HSCT). Uridine…”
Get full text

Effect of mismatching for mHA UTA2-1 on clinical outcome after HLA-identical sibling donor allo-SCT by Bosch-Vizcaya, A, Rodriguez-Romanos, R, Nieto, J B, de la Cámara, R, Brunet, S, Vallejo, C, Osca-Gelis, G, Martínez-Laperche, C, Buño, I, Urbano-Ispizúa, Á, González, M, Jiménez-Velasco, A, Gallardo, D

Get full text

A variant in IRF3 impacts on the clinical outcome of AML patients submitted to Allo-SCT by Martín-Antonio, B, Suarez-Lledo, M, Arroyes, M, Fernández-Avilés, F, Martínez, C, Rovira, M, Espigado, I, Gallardo, D, Bosch, A, Buño, I, Martínez-Laperche, C, Jiménez-Velasco, A, de la Cámara, R, Brunet, S, Nieto, J B, Urbano-Ispizua, Á

“…Allo-SCT has a strong curative potential for AML patients mainly due to a GVL effect. Unfortunately, GvL and GVHD are intimately linked. IFN regulatory…”
Get full text

Comparative study of BCR-ABL1 quantification: Xpert assay, a feasible solution to standardization concerns by López-Jorge, C. E., Gómez-Casares, M. T., Jiménez-Velasco, A., García-Bello, M. A., Barrios, M., Lopez, J., de la Iglesia, S., Ramírez, T., Sánchez, G., Heiniger, A. I., Molero, T.

“…The level of BCR-ABL1 reached after treatment with tyrosine kinase inhibitors is an effective marker of the therapeutic response and a good survival predictor…”
Get full text

ASPP1, a common activator of TP53, is inactivated by aberrant methylation of its promoter in acute lymphoblastic leukemia by Agirre, X, Roman-Gomez, J, Jimenez-Velasco, A, Garate, L, Montiel-Duarte, C, Navarro, G, Vazquez, I, Zalacain, M, Calasanz, M.J, Heiniger, A, Torres, A, Minna, J.D, Prosper, F

Get full text

Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia by Luna, A., Pérez-Lamas, L., Boque, C., Giraldo, P., Xicoy, B., Ruiz Nuño, C., Vega, M. Moreno, Alvarez-Larrán, A., Salamanca, A., García-Noblejas, A., Vall-Llovera, F., Villalon, L., De las Heras, N., Ramila, E., Pérez-Encinas, M., Cuevas, B., Perez-Lopez, R., Sanchez-Guijo, F., Jiménez-Velasco, A., Lakhwani, S., Casado, L. Felipe, Rosell, A., Escola, A., Fernández, M. J., Garcia-Hernandez, C., Cervero, C., Mora, E., Sagüés, M., Suarez-Varela, S., Vélez, P., Carrascosa Mastell, P., Bitaube, R. F., Serrano, L., Cortes, M., Vera Goñi, J.A, Steegmann, J. L., de Soria, V. Gomez Garcia, Alonso-Dominguez, J. M., Araujo, M. Colorado, Coll, A. Paz, Hernandez-Boluda, J.C, García-Gutiérrez, V.

“…Failure of second-generation tyrosine kinase inhibitors (2GTKI) is a challenging situation in patients with chronic myeloid leukemia (CML). Asciminib, recently…”
Get full text

Downregulation of the large tumor suppressor 2 gene is associated with poor prognosis in acute lymphoblastic leukemia by JIMENEZ-VELASCO, A, ROMAN-GOMEZ, J, AGIRRE, X, BARRIOS, M, NAVARRO, G, VAZQUEZ, I, PROSPER, F, TORRES, A, HEINIGER, A

Get full text

Transcriptional silencing of the Dickkopfs-3 (Dkk-3) gene by CpG hypermethylation in acute lymphoblastic leukaemia by ROMAN-GOMEZ, J, JIMENEZ-VELASCO, A, AGIRRE, X, CASTILLEJO, J. A, NAVARRO, G, BARRIOS, M, ANDREU, E. J, PROSPER, F, HEINIGER, A, TORRES, A

“…DKK-3: is a newly characterised mortalisation-related gene and an antagonist of the Wnt oncogenic signalling pathway whose expression is decreased in a variety…”
Get full text

Promoter hypomethylation of the LINE-1 retrotransposable elements activates sense/antisense transcription and marks the progression of chronic myeloid leukemia by Roman-Gomez, J, Jimenez-Velasco, A, Agirre, X, Cervantes, F, Sanchez, J, Garate, L, Barrios, M, Castillejo, J.A, Navarro, G, Colomer, D, Prosper, F, Heiniger, A, Torres, A

Get full text

Promoter hypermethylation and global hypomethylation are independent epigenetic events in lymphoid leukemogenesis with opposing effects on clinical outcome by Roman-Gomez, J, Jimenez-Velasco, A, Agirre, X, Castillejo, J A, Navarro, G, Garate, L, Jose-Eneriz, E San, Cordeu, L, Barrios, M, Prosper, F, Heiniger, A, Torres, A

Get full text

Reliable quantification of hematopoietic chimerism after allogeneic transplantation for acute leukemia using amplification by real-time PCR of null alleles and insertion deletion polymorphisms by JIMENEZ-VELASCO, A, BARRIOS, M, ROMAN-GOMEZ, J, NAVARRO, G, BUNO, I, CASTILLEJO, J. A, RODRIGUEZ, A. I, GARCIA-GEMAR, G, TORRES, A, HEINIGER, A. I

“…Increasing mixed chimerism (MC) after allogeneic stem cell transplantation (SCT) has been associated with a high risk of relapse in acute leukemia. We…”
Get full text

The normal epithelial cell-specific 1 ( ) gene, a candidate tumor suppressor gene on chromosome 19q13.3-4, is downregulated by hypermethylation in acute lymphoblastic leukemia by Roman-Gomez, J, Jimenez-Velasco, A, Agirre, X, Castillejo, J A, Barrios, M, Andreu, E J, Prosper, F, Heiniger, A, Torres, A

Get full text

PB1747 ASSESSMENT OF FLT3 MUTATION IN ACUTE MYELOID LEUKEMIA: RESULTS OF A SPANISH DELPHI PANEL SURVEY by Gómez‐Casares, M.T., De la Fuente Burguera, A., Barragán, E., Calasanz, M.J., Jiménez Velasco, A., Sanz, M.Á., Esteve, J., Serrano, J., Pratcorona, M., Sierra, J.

“…Background: Despite the value of FLT3 as selective marker that drives therapy and current guidelines recommendations of FLT3 testing in all patients with AML,…”
Get full text

PF408 DASFREE 2‐YEAR UPDATE: DASATINIB DISCONTINUATION IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML‐CP) AND DEEP MOLECULAR RESPONSE (DMR) by Shah, N., García‐Gutiérrez, J.V., Jiménez‐Velasco, A., Larson, S., Saussele, S., Rea, D., Mahon, F.‐X., Levy, M.Y., Gómez‐Casares, M.T., Luciano, L., Nicolini, F.‐E., Mauro, M.J., Sy, O., Martin‐Regueira, P., Lipton, J.H.

“…Background: Treatment‐free remission (TFR) is a potential treatment goal for pts with CML‐CP. Sustained TFR has previously been reported for pts enrolled in…”
Get full text